<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00469703</url>
  </required_header>
  <id_info>
    <org_study_id>Chronic Pancreatitis</org_study_id>
    <nct_id>NCT00469703</nct_id>
  </id_info>
  <brief_title>Safety and Efficacy Study of Thalomid in Patients With Chronic Pancreatitis</brief_title>
  <official_title>A Phase II, Open-Label, Single Center Pilot Study to Determine the Safety and Efficacy of THALOMID (Thalidomide) in Patients With Chronic Pancreatitis.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Winthrop University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Celgene Corporation</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Winthrop University Hospital</source>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine if Thalidomide (Thalomid) is effective in treating&#xD;
      patients with chronic pancreatitis.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Pancreatitis is an inflammation of the pancreas, a gland that lies behind the stomach. The&#xD;
      inflammation may develop suddenly (acute pancreatitis) or over many years (chronic&#xD;
      pancreatitis). The pancreas produces the hormones, insulin and glucagon to control&#xD;
      metabolism. The hormones and enzymes flow from the pancreas through the pancreatic duct into&#xD;
      the upper part of the small intestine.&#xD;
&#xD;
      Most chronic pancreatitis patients often experience chronic abdominal pain during the course&#xD;
      of the disease. Thalidomide increased the production of interleukin-10 (IL-10), which is&#xD;
      important in regulating intestinal inflammation. Thalidomide is approved by the Food and Drug&#xD;
      Administration (FDA) for a leprosy skin condition, erythema nodosum lerosum (ENL), but not&#xD;
      for the treatment of chronic pancreatitis. In this case it is considered experimental.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Terminated&#xD;
  </why_stopped>
  <start_date>August 2005</start_date>
  <completion_date type="Actual">November 2007</completion_date>
  <primary_completion_date type="Actual">November 2007</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety and efficacy</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>reduction of frequency of hospitalizations</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>quality of life</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>reduction of pain</measure>
  </secondary_outcome>
  <enrollment type="Anticipated">10</enrollment>
  <condition>Chronic Pancreatitis</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Thalidomide</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Age 18-75, inclusive.&#xD;
&#xD;
          2. Female must be post menopausal (≥ 24 months without menses or surgically sterilized).&#xD;
&#xD;
          3. Able to comprehend English.&#xD;
&#xD;
          4. Chronic pancreatic pain lasting for more than 2 months.&#xD;
&#xD;
          5. History of chronic pancreatitis with pancreatic type pain confirmed by at least one of&#xD;
             the following:&#xD;
&#xD;
               -  Histological confirmation&#xD;
&#xD;
               -  CT/MRI (including calcifications, dilated cuts, dilated MPD, and /or atrophy)&#xD;
&#xD;
               -  ERCP with Cambridge score of 2 or greater&#xD;
&#xD;
          6. Subject must score at least 4 cm on the VAS scale during the 1-2 week lead-in-period.&#xD;
&#xD;
          7. Patients must give written informed consent.&#xD;
&#xD;
          8. Patients must be willing and able to comply with the FDA-mandated S.T.E.P.S.® program.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Female of child-bearing potential.&#xD;
&#xD;
          2. Unable to comprehend English.&#xD;
&#xD;
          3. Patients with diabetes requiring insulin.&#xD;
&#xD;
          4. Evidence of gallstones on screening ultrasonography.&#xD;
&#xD;
          5. Current alcohol abuse or addiction to opiate analgesics.&#xD;
&#xD;
          6. Patients with existing peripheral neuropathy.&#xD;
&#xD;
          7. Patients who are taking medications known to be associated with development of&#xD;
             neuropathy: Amiodarone, hydralazine, perhexiline, vincristine, cisplatin,&#xD;
             Metronidazole (Flagyl), Dapsone, Phenytoin and Disulfiram.&#xD;
&#xD;
          8. Patients who have pre-existing hypercoagulable state. Patients with a history of&#xD;
             malignancy within the past 5 years, patients with a recent surgical procedure,&#xD;
             patients with chronic immobilization causing blood stasis, patients with history of&#xD;
             embolism or deep vein thrombosis, patients with extreme heart failure, and patients&#xD;
             with a congenital disorder of the clotting cascade.&#xD;
&#xD;
          9. Patients with active alcoholic liver disease or elevated liver function &gt;3Xs the upper&#xD;
             limit of normal.&#xD;
&#xD;
         10. Patients will be withdrawn from the study at Visit 4 (Month 3) if pain score on VAS&#xD;
             scale has not improved.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>James H Grendell, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Winthrop University Hospital</affiliation>
  </overall_official>
  <removed_countries>
    <country>United States</country>
  </removed_countries>
  <verification_date>January 2008</verification_date>
  <study_first_submitted>May 3, 2007</study_first_submitted>
  <study_first_submitted_qc>May 3, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 4, 2007</study_first_posted>
  <last_update_submitted>January 10, 2008</last_update_submitted>
  <last_update_submitted_qc>January 10, 2008</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 16, 2008</last_update_posted>
  <keyword>Pancreatitis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pancreatitis</mesh_term>
    <mesh_term>Pancreatitis, Chronic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Thalidomide</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

